ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Ann Surg Oncol 2023 May;30(5):3022
Date
03/07/2023Pubmed ID
36877324DOI
10.1245/s10434-023-13160-9Scopus ID
2-s2.0-85152164746 (requires institutional sign-in at Scopus site)Author List
Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai SAuthors
Kathleen K. Christians MD Professor in the Surgery department at Medical College of WisconsinCallisia N. Clarke MD Chief, Associate Professor in the Surgery department at Medical College of Wisconsin
Beth A. Erickson MD Professor in the Radiation Oncology department at Medical College of Wisconsin
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of Wisconsin
Ben George MD Professor in the Medicine department at Medical College of Wisconsin
William Adrian Hall MD Professor in the Radiation Oncology department at Medical College of Wisconsin
Mandana Kamgar MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Zachary Smith DO Associate Professor in the Medicine department at Medical College of Wisconsin
Parag P. Tolat MD Chief, Associate Professor in the Radiology department at Medical College of Wisconsin